We are honoured to have been selected to tell our story at the upcoming Respiratory Innovation Summit on May 17! RIS Agenda Pulmocide’s CSO, Dr. Pete Strong will be presenting […]
Company news
Pulmocide announces the initiation of a double-blind, placebo-controlled study to evaluate the effects of PC945 on fungal burden in a moderate-severe asthma population with Aspergillus fumigatus infection. PC945 will be […]
17 January 2019
Funding to progress novel wholly-owned compounds for RSV and pulmonary Aspergillosis London, UK, 20 March 2017: Pulmocide Ltd, the UK-based drug discovery company developing novel compounds designed for inhaled […]
20 March 2017